MX2014015899A - Capsula de estradiol soluble para insercion por via vaginal. - Google Patents
Capsula de estradiol soluble para insercion por via vaginal.Info
- Publication number
- MX2014015899A MX2014015899A MX2014015899A MX2014015899A MX2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A MX 2014015899 A MX2014015899 A MX 2014015899A
- Authority
- MX
- Mexico
- Prior art keywords
- vaginal insertion
- soluble estradiol
- capsule
- estradiol capsule
- soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
De conformidad con varias modalidades de la presente descripción, se presentan formulaciones farmacéuticas que comprenden estradiol solubilizado. En varias modalidades, dichas formulaciones se encapsulan en cápsulas blandas que pueden insertarse por vía vaginal para el tratamiento de la atrofia vulvovaginal.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661302P | 2012-06-18 | 2012-06-18 | |
US201261662265P | 2012-06-20 | 2012-06-20 | |
US13/684,002 US8633178B2 (en) | 2011-11-23 | 2012-11-21 | Natural combination hormone replacement formulations and therapies |
US201261745313P | 2012-12-21 | 2012-12-21 | |
PCT/US2013/023309 WO2013112947A1 (en) | 2012-01-26 | 2013-01-25 | Transdermal hormone replacement therapies |
US13/843,428 US9301920B2 (en) | 2012-06-18 | 2013-03-15 | Natural combination hormone replacement formulations and therapies |
PCT/US2013/046443 WO2013192249A1 (en) | 2012-06-18 | 2013-06-18 | Soluble estradiol capsule for vaginal insertion |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014015899A true MX2014015899A (es) | 2015-03-03 |
MX358435B MX358435B (es) | 2018-08-03 |
Family
ID=49769313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014015899A MX358435B (es) | 2012-06-18 | 2013-06-18 | Capsula de estradiol soluble para insercion por via vaginal. |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP3909586A1 (es) |
JP (3) | JP6397402B2 (es) |
AU (3) | AU2013277234B2 (es) |
BR (1) | BR112014031914B1 (es) |
CA (1) | CA2876968C (es) |
ES (1) | ES2869250T3 (es) |
HR (1) | HRP20210861T1 (es) |
HU (1) | HUE055275T2 (es) |
IL (1) | IL236359B (es) |
MX (1) | MX358435B (es) |
PL (1) | PL2861073T3 (es) |
RU (2) | RU2020140867A (es) |
WO (1) | WO2013192249A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
JP2018538290A (ja) * | 2015-12-07 | 2018-12-27 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 膣挿入エストラジオール医薬組成物および方法 |
WO2017105512A1 (en) * | 2015-12-18 | 2017-06-22 | Proinvet Innovations S.A. | Formulations and methods for controlling the reproductive cycle and ovulation |
RU2018133932A (ru) | 2016-04-01 | 2020-05-12 | Терапьютиксмд, Инк. | Фармацевтическая композиция стероидного гормона |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
EP4051203A4 (en) * | 2019-10-31 | 2023-10-25 | R.P. Scherer Technologies, LLC | SUPPOSITORY CAPSULE |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US694192A (en) * | 1901-04-20 | 1902-02-25 | William C Rastetter | Vehicle-wheel. |
IT1090703B (it) * | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | Perfezionamento nelle composizioni utili quali veicolo per farmaci |
US4384096A (en) * | 1979-08-27 | 1983-05-17 | The Dow Chemical Company | Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems |
FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2728464B1 (fr) * | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
FR2739558B1 (fr) | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale |
GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
US6018033A (en) | 1997-05-13 | 2000-01-25 | Purdue Research Foundation | Hydrophilic, hydrophobic, and thermoreversible saccharide gels and forms, and methods for producing same |
NZ330726A (en) * | 1998-06-18 | 2000-10-27 | Dec Res | Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US20030083286A1 (en) * | 2001-08-22 | 2003-05-01 | Ching-Leou Teng | Bioadhesive compositions and methods for enhanced intestinal drug absorption |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20060134188A1 (en) * | 2004-12-20 | 2006-06-22 | Hans-Peter Podhaisky | Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient |
US20070036843A1 (en) * | 2005-01-28 | 2007-02-15 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
WO2007076144A2 (en) * | 2005-12-27 | 2007-07-05 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
US20070264349A1 (en) * | 2006-03-07 | 2007-11-15 | Novavax, Inc. | Nano-structured compositions and methods of making and using the same |
FR2900052B1 (fr) * | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
US20070287789A1 (en) * | 2006-06-07 | 2007-12-13 | Stephen Ray Jones | Bleed-resistant colored microparticles |
CN101474167A (zh) * | 2009-01-23 | 2009-07-08 | 西安德天药业股份有限公司 | 雌二醇阴道用胶囊的制备方法 |
US9301920B2 (en) * | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
RS62297B1 (sr) * | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
-
2013
- 2013-06-18 ES ES13807188T patent/ES2869250T3/es active Active
- 2013-06-18 JP JP2015517489A patent/JP6397402B2/ja active Active
- 2013-06-18 PL PL13807188T patent/PL2861073T3/pl unknown
- 2013-06-18 HU HUE13807188A patent/HUE055275T2/hu unknown
- 2013-06-18 RU RU2020140867A patent/RU2020140867A/ru unknown
- 2013-06-18 EP EP21167943.6A patent/EP3909586A1/en not_active Withdrawn
- 2013-06-18 CA CA2876968A patent/CA2876968C/en active Active
- 2013-06-18 AU AU2013277234A patent/AU2013277234B2/en active Active
- 2013-06-18 EP EP13807188.1A patent/EP2861073B1/en not_active Revoked
- 2013-06-18 WO PCT/US2013/046443 patent/WO2013192249A1/en active Application Filing
- 2013-06-18 BR BR112014031914-6A patent/BR112014031914B1/pt active IP Right Grant
- 2013-06-18 RU RU2015100531A patent/RU2740059C2/ru active
- 2013-06-18 MX MX2014015899A patent/MX358435B/es active IP Right Grant
-
2014
- 2014-12-18 IL IL236359A patent/IL236359B/en active IP Right Grant
-
2017
- 2017-07-27 AU AU2017208300A patent/AU2017208300A1/en not_active Abandoned
-
2018
- 2018-08-31 JP JP2018162966A patent/JP6682127B2/ja active Active
-
2019
- 2019-06-28 AU AU2019204653A patent/AU2019204653B2/en not_active Ceased
-
2020
- 2020-02-26 JP JP2020030544A patent/JP2020100642A/ja active Pending
-
2021
- 2021-05-31 HR HRP20210861TT patent/HRP20210861T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013277234A1 (en) | 2015-01-22 |
EP3909586A1 (en) | 2021-11-17 |
EP2861073A1 (en) | 2015-04-22 |
JP2018199711A (ja) | 2018-12-20 |
JP6682127B2 (ja) | 2020-04-15 |
CA2876968A1 (en) | 2013-12-27 |
HUE055275T2 (hu) | 2021-11-29 |
RU2740059C2 (ru) | 2020-12-31 |
CA2876968C (en) | 2022-09-13 |
IL236359A0 (en) | 2015-02-26 |
MX358435B (es) | 2018-08-03 |
EP2861073A4 (en) | 2015-12-23 |
AU2013277234B2 (en) | 2017-04-27 |
AU2019204653A1 (en) | 2019-07-18 |
ES2869250T3 (es) | 2021-10-25 |
JP6397402B2 (ja) | 2018-09-26 |
JP2015519405A (ja) | 2015-07-09 |
EP2861073B1 (en) | 2021-04-14 |
BR112014031914B1 (pt) | 2021-12-14 |
AU2019204653B2 (en) | 2021-07-08 |
RU2020140867A (ru) | 2021-06-10 |
BR112014031914A2 (pt) | 2017-06-27 |
HRP20210861T1 (hr) | 2021-09-17 |
PL2861073T3 (pl) | 2021-09-27 |
AU2017208300A1 (en) | 2017-08-17 |
JP2020100642A (ja) | 2020-07-02 |
WO2013192249A1 (en) | 2013-12-27 |
RU2015100531A (ru) | 2016-08-10 |
IL236359B (en) | 2020-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014015899A (es) | Capsula de estradiol soluble para insercion por via vaginal. | |
MX2018002301A (es) | Composiciones de glucano y usos de las mismas. | |
MY193729A (en) | Pharmaceutical compositions | |
TN2012000161A1 (en) | Spiro-oxindole mdm2 antagonists | |
UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
MX366899B (es) | Nuevos compuestos. | |
MX2015000813A (es) | Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona. | |
MX2013004061A (es) | Analogos de ciclosporina. | |
MX2012001660A (es) | Formulaciones que contienen linaclotida para adminstracion oral. | |
PH12015501096A1 (en) | Composition for immediate and extended release | |
IN2013MU03583A (es) | ||
IN2014DN06737A (es) | ||
MX2016005092A (es) | Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos. | |
MX2013004062A (es) | Analogos de ciclosporina. | |
EP2410336A4 (en) | BREAST CANCER DIAGNOSTIC MARKER COMPRISING THERODOXIN-1 AS ACTIVE INGREDIENT AND BREAST CANCER DIAGNOSTIC KIT USING THE SAME | |
MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
EP3250214A4 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
IN2012DE00826A (es) | ||
MX2013010415A (es) | Tratamiento de la atrofia vaginal con nueva indicacion para la mirra. | |
GB2501427A (en) | A washing capsule for providing washing compositions to a machine | |
MX2022002614A (es) | El uso de un pesario que comprende una capsula que contiene estradiol y un agente solubilizante para el tratamiento de la atrofia vulvovaginal. | |
IN2014DN07897A (es) | ||
PH12015500070A1 (en) | Pediatric oral liquid compositions containing nepadutant | |
TN2010000445A1 (en) | Oral and injectable formulations of tetracycline compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |